EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Journal Club: Mastocytosis: across the spectrum: pathobiology, clinical evaluation, and evolving therapies

Luis Jiménez Briones, Belén Rodríguez Sánchez, Jorge Martín-Nieto González, Luis Zamarro Díaz, Marina De La Puente Alonso, Simon Goller, Cesar Silva Ferreira, Paloma García Piqueras

European Journal of Dermatology · 2025

DOI: 10.1684/ejd.2025.5005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Dermatology, 2025. Verfasst von Luis Jiménez Briones und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Hauptthemen laut MEDLINE: Mastocytosis, Systemic, Mastocytosis, Cutaneous, Mastocytosis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mastocytosis encompasses a heterogeneous group of clonal mast cell disorders ranging from cutaneous forms in children to advanced systemic mastocytosis (AdvSM) with significant morbidity. This review covers epidemiology, pathogenesis, diagnosis, and management, integrating World Health Organization (WHO)/International Consensus Classification (ICC) 2022 classification updates, molecular insights, and therapeutic advances. Pediatric cutaneous mastocytosis (CM) usually has a favourable prognosis and often resolves spontaneously, whereas adult-onset disease frequently reflects systemic involvement and warrants bone marrow biopsy. KIT D816V and non-D816V variants serve as key diagnostic and prognostic markers, guiding targeted therapy. Midostaurin and avapritinib have reshaped the treatment of AdvSM, while next-generation tyrosine-kinase inhibitors (TKIs) are in clinical trials. Multidisciplinary care is critical, and knowledge gaps remain in paediatric risk stratification, optimal sequencing of therapies, and disease progression assessment. This review highlights recent advances and future priorities for personalized, evidence-based care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mastocytosis, SystemicMastocytosis, CutaneousMastocytosisHumansProtein Kinase InhibitorsAvapritinibProto-Oncogene Proteins c-kitPrognosisChild

Substanzen

Protein Kinase InhibitorsAvapritinibProto-Oncogene Proteins c-kit

Autor:innen und Institutionen

  • Department of Dermatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.
  • Department of Dermatology, Unidade Local de Saúde de Santo António, Porto, Portugal.
  • Department of Dermatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.

Zitieren

APA

Briones, L. J., Sánchez, B. R., González, J. M., Díaz, L. Z., Alonso, M. P., Goller, S., Ferreira, C. S., & Piqueras, P. G. (2025). Journal Club: Mastocytosis: across the spectrum: pathobiology, clinical evaluation, and evolving therapies. European Journal of Dermatology. https://doi.org/10.1684/ejd.2025.5005

Vancouver

Briones LJ, Sánchez BR, González JM, Díaz LZ, Alonso MP, Goller S, et al. Journal Club: Mastocytosis: across the spectrum: pathobiology, clinical evaluation, and evolving therapies. European Journal of Dermatology. 2025. doi:10.1684/ejd.2025.5005

BibTeX
@article{Briones2025,
  author = {Briones, Luis Jiménez and Sánchez, Belén Rodríguez and González, Jorge Martín-Nieto and Díaz, Luis Zamarro and Alonso, Marina De La Puente and Goller, Simon and Ferreira, Cesar Silva and Piqueras, Paloma García},
  title = {Journal Club: Mastocytosis: across the spectrum: pathobiology, clinical evaluation, and evolving therapies},
  journal = {European Journal of Dermatology},
  year = {2025},
  doi = {10.1684/ejd.2025.5005}
}
Kostenlos starten →